Literature DB >> 20033345

Myoglobinuria after laparoscopic radiofrequency ablation of liver tumors.

John Rodriguez1, Gurkan Tellioglu, Allan Siperstein, Eren Berber.   

Abstract

BACKGROUND: There are scant data in the literature about myoglobinuria after radiofrequency ablation (RFA) of liver tumors. The aim of this study is to analyze the incidence and identify the risk factors involved in this complication after RFA. PATIENTS AND METHODS: An initial case of myoglobinuria and acute kidney injury (AKI) during laparoscopic liver RFA after 10 years of the liver ablation program led to the design of this study. Prospective data were collected on 41 consecutive patients undergoing laparoscopic RFA at our institution over a 9-month period. Urine myoglobin, serum creatinine kinase, and serum creatinine levels were obtained preablation and postablation. Variables were compared between patients to identify possible risk factors that might be related to this rare complication. Data are expressed as mean +/- standard error of the mean.
RESULTS: Two patients were excluded from the study due to preoperative myoglobinuria of unknown etiology. Of the remaining 39 patients, three developed dark urine with significant myoglobinuria on postoperative day 1. Two of these patients had carcinoid liver metastases; the remaining patient had a metastatic colorectal lesion. The number of tumors ablated in these patients was 14, 11, and 3 vs. 2.4 +/- 0.4 in the rest of the patients. Cumulative tumor volume was larger in the group of patients that developed the complication vs. those who did not (127.9 +/- 59.5 vs. 48 +/- 3 cm(3)). Two grounding pads were used in the three patients that had a complication vs. four pads in the rest of the patients. Dark urine was identified promptly intraoperatively and treated aggressively. All of these patients required intensive care unit (ICU) admission and had a prolonged hospital stay. Marked elevation of transaminases and creatinine kinase as well as a drop in hematocrit and platelet count was observed in patients with myoglobinuria. In our retrospective review of 706 patients that underwent liver RFA in the past 10 years, we detected 27 patients (3.8%) with ten or more lesions (11.9 +/- 0.4). None of these patients had significant elevation of serum creatinine postoperatively. In the whole series of 706 patients, 22 (3.2%) were found to have elevated creatinine after liver RFA, with return to baseline in all but seven patients in follow-up.
CONCLUSION: Myoglobinuria after liver RFA is a rare but potentially devastating complication that may lead to AKI with significant morbidity and prolonged hospital stay. Patients with large tumor volumes requiring longer ablation times need to be monitored closely for the development of this complication. The fact that this was not observed in other patients with similar tumor characteristics suggests that individual patient-related factors might play an important role.

Entities:  

Mesh:

Substances:

Year:  2009        PMID: 20033345     DOI: 10.1007/s11605-009-1118-x

Source DB:  PubMed          Journal:  J Gastrointest Surg        ISSN: 1091-255X            Impact factor:   3.452


  11 in total

1.  Radiofrequency ablation: the experts weigh in.

Authors:  Kenneth K Tanabe; Steven A Curley; Gerald D Dodd; Allan E Siperstein; S Nahum Goldberg
Journal:  Cancer       Date:  2004-02-01       Impact factor: 6.860

Review 2.  Rhabdomyolysis: diagnosis and treatment in bariatric surgery.

Authors:  João E M T M Ettinger; Carlos A Marcílio de Souza; Paulo V Santos-Filho; Euler Azaro; Carlos A B Mello; Edvaldo Fahel; Paulo B P Batista
Journal:  Obes Surg       Date:  2007-04       Impact factor: 4.129

Review 3.  Complications of radiofrequency coagulation of liver tumours.

Authors:  S Mulier; P Mulier; Y Ni; Y Miao; B Dupas; G Marchal; I De Wever; L Michel
Journal:  Br J Surg       Date:  2002-10       Impact factor: 6.939

4.  Safety and efficacy of radiofrequency thermal ablation in advanced liver tumors.

Authors:  B J Bowles; J Machi; W M Limm; R Severino; A J Oishi; N L Furumoto; L L Wong; R H Oishi
Journal:  Arch Surg       Date:  2001-08

5.  Rhabdomyolysis following laparoscopic gastric bypass.

Authors:  D Filis; M Daskalakis; I Askoxylakis; M Metaxari; J Melissas
Journal:  Obes Surg       Date:  2005 Nov-Dec       Impact factor: 4.129

6.  Rhabdomyolysis and acute myoglobinuric renal failure in a patient with bilateral pheochromocytoma following open pyelolithotomy.

Authors:  Inan Anaforoglu; M Eda Ertorer; Filiz E Haydardedeoglu; Tamer Colakoglu; Naime Tokmak; Nilgun G Demirag
Journal:  South Med J       Date:  2008-04       Impact factor: 0.954

7.  Treatment of focal liver tumors with percutaneous radio-frequency ablation: complications encountered in a multicenter study.

Authors:  Tito Livraghi; Luigi Solbiati; M Franca Meloni; G Scott Gazelle; Elkan F Halpern; S Nahum Goldberg
Journal:  Radiology       Date:  2003-02       Impact factor: 11.105

8.  Major complications of ultrasound-guided percutaneous radiofrequency ablations for liver malignancies: single center experience.

Authors:  Tsung-Ming Chen; Pi-Teh Huang; Lien-Fu Lin; Jai-Nien Tung
Journal:  J Gastroenterol Hepatol       Date:  2007-08-07       Impact factor: 4.029

9.  Early and late complications after radiofrequency ablation of malignant liver tumors in 608 patients.

Authors:  Steven A Curley; Paolo Marra; Karen Beaty; Lee M Ellis; J Nicolas Vauthey; Eddie K Abdalla; Courtney Scaife; Chan Raut; Robert Wolff; Haesun Choi; Evelyne Loyer; Paolo Vallone; Francesco Fiore; Fabrizio Scordino; Vincenzo De Rosa; Raffaele Orlando; Sandro Pignata; Bruno Daniele; Francesco Izzo
Journal:  Ann Surg       Date:  2004-04       Impact factor: 12.969

10.  Perioperative outcome after laparoscopic radiofrequency ablation of liver tumors: an analysis of 521 cases.

Authors:  E Berber; A E Siperstein
Journal:  Surg Endosc       Date:  2007-02-08       Impact factor: 3.453

View more
  1 in total

1.  Radiofrequency ablation for treatment of hypersplenism: A feasible therapeutic option.

Authors:  Guilherme Lopes P Martins; Joao Paulo G Bernardes; Marcello S Rovella; Raphael G Andrade; Publio Cesar C Viana; Paulo Herman; Giovanni Guido Cerri; Marcos Roberto Menezes
Journal:  World J Gastroenterol       Date:  2015-05-28       Impact factor: 5.742

  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.